Fig. 2.

SARA is dispensable for neurogenesis and daughter cell fate. (A) Mouse brain slices electroporated at E13.5 with Ctrolsh or SARAsh and harvested 40 h later. (B-D) Cell cycle exit analysis. (B) Percentage of GFP⁺ BrdU⁺ Ki67⁻ cells among total GFP⁺ BrdU⁺ cells (cell cycle exit index). Data are means±s.e.m. P=0.84, t-test. At least 112 cells from three brains were counted for each condition. (C,D) Representative confocal microscopy images of transfected mouse cortical slices subjected to cell cycle exit analysis. GFP⁺ cells (green) 24 h after BrdU treatment (magenta) and stained with antibodies against Ki67 (red). Arrowheads point to cells positive for GFP and BrdU but negative for Ki67. Arrows point to cells positive for GFP, BrdU and Ki67. (E-H) Mouse brain slices electroporated at E13.5 with Ctrolsh or SARAsh and harvested 40 h later were co-labeled for Pax6, Tbr2, PH3 or Tuj1 (red). (I-L) Percentage of GFP⁺ cells transfected with the indicated plasmids that were positive for Pax6 (I), Tbr2 (J), PH3 (K) and Tuj1 (L). Data are mean±s.e.m. At least three brains were analyzed for each condition. No significant difference was found between transfections for the indicated immunolabelings: P=0.83 (I), P=0.44 (J), P=0.78 (K) and P=0.82 (L), t-tests. Scale bars: 100 µm in A; 20 µm in C,D; 50 µm in E-H.